| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03400176 Details | 2023-11-14 Interventional | 1 | 39 | Ibrutinib Leukemia Leukemia, Lymph… Leukemia, Lymph… Chronic Lymphoc… | Business reasons - | |||
| NCT05929716 Details | 2023-11-13 Interventional | 2 | 0 | Magrolimab Rituximab Lymphoma Lymphoma, B-Cel… B-cell Lymphoma Large B-cell Ly… | Per Principal Investigator request - | |||
| NCT04988308 2020-002607-19 Details | 2023-11-13 Interventional | 2 | 151 | Adalimumab Hidradenitis Hidradenitis Su… | Study has been prematurely terminated as the Interim Analysis 1 efficacy results met the
prespecified futility criteria related to the primary endpoint. As per change in planned analysis, Part 2 and some secondary efficacy analysis of Part 1 in this study was not conducted due to early termination because interim analysis 1 efficacy results met the prespecified futility criteria related to the primary endpoint. Hence, data for Part 2 and some secondary efficacy outcome measures (Parts 1 and 2) were not collected in this results summary. | |||
| NCT04737109 Details | 2023-11-13 Interventional | 1/2 | 6 | Androgens Ipatasertib Prostatic Neopl… Castrate Resist… | Funder Decision - | |||
| NCT04582669 Details | 2023-11-13 Interventional | 4 | 11 | Triamcinolone Triamcinolone A… Triamcinolone d… Triamcinolone h… Hidradenitis Hidradenitis Su… | This study was administratively closed. - | |||
| NCT04329806 Details | 2023-11-13 Interventional | 1 | - | Amlodipine Moxonidine Insulin Resista… Obesity Obesity-Associa… | Study being replaced by crossover design - | |||
| NCT03845894 Details | 2023-11-13 Interventional | 4 | 25 | Bupivacaine Shoulder Arthro… | feasibility - | |||
| NCT03299842 Details | 2023-11-13 Interventional | 3 | 5 | Fenfluramine Epilepsies, Myo… Seizures Syndrome Dravet Syndrome | The study was stopped due to low enrollment. No data will be reported, as the exploratory sub-study was investigating a rare disease in pediatrics with a high risk of participant identification due to low enrolment (participant privacy/confidentiality issue). Safety Data for eligible participants in the sub-study was collected in the main study ZX008-1503 (NCT02823145) as pre-specified in the protocol. The data will be disclosed with the main study results posting. | |||
| NCT03237611 Details | 2023-11-13 Interventional | 2 | 15 | Aprepitant Dexamethasone Fosaprepitant Ondansetron Nausea Vomiting Chemotherapy-in… | Expired IRB approval on 2/11/21 - | |||
| NCT06050954 Details | 2023-11-09 Interventional | 2 | 0 | Pembrolizumab Carcinoma, Tran… Urinary Bladder… Metastatic Urot… | Change in standard of care. - | |||
| NCT04865419 2020-005106-25 Details | 2023-11-09 Interventional | 1/2 | 46 | Voriconazole Hematologic Neo… Neoplasms Haematological … | Trial terminated based on benefit-risk profile assessment - | |||
| NCT04218825 2019-004891-20 Details | 2023-11-09 Interventional | 2 | 2 | Mechlorethamine Lymphoma Lymphoma, T-Cel… Lymphoma, T-Cel… Lymphoma, T-Cel… Mycoses Mycosis Fungoid… Early Stage Myc… | After an extensive assessment of the study feasibility, it was decided to discontinue the
clinical trial due to poor recruitment. - | |||
| NCT03969420 Details | 2023-11-09 Interventional | 2 | 11 | Alvocidib Cytarabine Leukemia Leukemia, Myelo… Leukemia, Myelo… Acute Myeloid L… | Business decision to terminate the development of alvocidib program on 17 November 2020.
Patients permitted on treatment until April 22, 2021. The last end-of-treatment follow-up
completed on May 14, 2021. - | |||
| NCT03593915 Details | 2023-11-09 Interventional | 1/2 | 20 | Alvocidib Azacitidine Decitabine Myelodysplastic… Preleukemia Myelodysplastic… | The sponsor decided not to continue the study based on the overall company strategy in AML. A business decision was made to stop enrollment and the study was discontinued on 17 November 2020. Consistent with Food and Drug Administration and International Council for Harmonisation guidance on the content for abbreviated and synoptic CSRs, only safety data are analyzed and reported. | |||
| NCT03572634 Details | 2023-11-09 Interventional | 1/2 | 3 | Ibrutinib Leukemia Leukemia, Lymph… Leukemia, Lymph… CLL Chronic Lymphoc… SLL Small Lymphocyt… | Given the extensive time projected to conclude the study hypothesis, it is no longer feasible
to include this study of TP-0903. The study was stopped early (21 January 2020) due to low enrollment. | |||
| NCT01121588 2010-022978-14 Details | 2023-11-09 Interventional | 1 | 44 | Crizotinib Lymphoma Neoplasms Neoplasms Malig… | Termination of further treatment on the study due to the availability of commercial supply or a
rollover study (NCT05160922) that will allow active subjects to continue receiving treatment. - | |||
| NCT05905341 Details | 2023-11-08 Interventional | 1 | 0 | Fulvestrant Breast Neoplasm… Liposarcoma Breast Cancer Endometrial Non-small Cell … Ovarian Cancer Solid Tumors | This decision was based on business considerations and not due to specific safety reasons or a
request from a regulatory authority. - | |||
| NCT05728736 Details | 2023-11-08 Interventional | 2 | 0 | Lemborexant Alzheimer Disea… | Study was terminated due to enrollment difficulties and the inability to obtain necessary study
supplies. Five participants signed consent; however, no one was randomized. The study was
officially terminated with the funding source on 10/04/2023. - | |||
| NCT05466539 Details | 2023-11-08 Interventional | 4 | - | Botulinum Toxin… abobotulinumtox… Chronic Exertio… Compartment Syn… Syndrome Compartment Syn… | Study suspended pending approval of a protocol amendment prior to beginning recruitment. - | |||
| NCT05375760 2022-001014-20 Details | 2023-11-07 Interventional | 2 | 251 | Cilgavimab and … COVID-19 Coronavirus Dis… | Sponsor terminated after review of FDA's request to halt further dosing (30Mar2023) given that
AZD7442 is not active against >99% of the currently circulating SARS-CoV-2 variants in the USA,
the benefit risk assessment may not be favorable - |